As summarized in Table 1, EC0746 treatment on days 10, 13, 17, and 20 displayed an ~10-fold linear dose response from 25too 250 nmol/kg, with R2 values of 1.00 (percentage inhibition in paw edema) and 0.99 (reduction in splenomegaly), respectively.
Mosquito coils, repellents, and citronella candles each decreased risk by at least 2-fold, with a dose response for the number of protective measures used.
There was a clear dose response in the fold increase to each antigen, as the MD-EP IFNγ ELISPOT responses to Env, Pol, Gag, and Nef-Tat increased by 40, 7, 3, and 5-fold over HD-IM responses, respectively.
Serum alanine aminotransferase (ALT) elevation did not show any dose response over a 12-fold dose range up to 24 hr.
GC treatment was performed in 15-point dose response using a three-fold dilution series starting with a maximum compound concentration of 10 μM.
For both histological subtypes, current smokers displayed a more than two-fold increased risk of HL but no dose – response relationship was observed.
These results suggest that amplification may be in the range of five-fold for the arthritis models, assuming a linear dose response.
Flunarizine produced a parallel shift in the X-ray dose response curve, equivalent to a 5-fold reduction in hypoxic fraction.
Because liquid broth MIC90 dose response curves often have a 2-fold variation between biological replicates, significant differences in MIC90 are generally considered to be those that are >4-fold.
The sigmoid dose response curve spans only around a ten-fold concentration range.
Full dose response curves reveal that AM1 is more potent than ABA (8.7-fold) and Pyrabactin (7.6-fold), respectively, in promoting PYR1-HAB1 interaction, while AM2 and AM3 have relatively weaker potencies than AM1.
